Overview
No overview information available.
Indication
适用于产β内酰胺酶而对哌拉西林耐药、但对本品敏感的细菌（如大肠埃希菌、克雷伯菌属、柠檬酸杆菌属、肠杆菌属、沙雷菌属、变形杆菌属、摩根菌属、雷极普罗维登菌、铜绿假单胞菌、流感嗜血杆菌、不动杆菌属、葡萄球菌属和拟杆菌属等）所致的下列中、重度感染： 1.肺炎、肺脓肿、脓胸、支气管扩张合并感染和慢性阻塞性肺病继发性感染等下呼吸道感染； 2.创伤或外科伤口继发皮肤软组织感染、蜂窝织炎、皮肤脓肿、糖尿病足感染； 3.胆囊炎、胆管炎、肝脓肿和腹膜炎等腹腔感染； 4.盆腔炎、子宫内膜炎、子宫周围炎、附件炎、盆腔脓肿等生殖系统感染； 5.单纯或复杂性尿路感染。本品用于铜绿假单胞菌严重感染时，应联合氨基糖苷类等其他抗铜绿假单胞菌的药物。
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/05/01 | Phase 4 | Not yet recruiting | |||
2024/12/02 | Phase 4 | Not yet recruiting | University Hospital, Akershus | ||
2024/11/15 | Phase 4 | Recruiting | CR-CSSS Champlain-Charles-Le Moyne | ||
2024/03/05 | Phase 4 | Recruiting | |||
2021/07/30 | Phase 2 | Completed | |||
2020/02/19 | Not Applicable | Completed | University Hospital, Bordeaux | ||
2020/01/21 | Phase 4 | UNKNOWN | Hospital Universitari de Bellvitge | ||
2019/04/22 | N/A | Terminated | |||
2019/03/05 | Phase 2 | Withdrawn | |||
2018/04/03 | Phase 2 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Piperacillin Sodium and Tazobactam Sodium for Injection(4:1) | 国药准字H20213900 | 化学药品 | 注射剂 | 11/24/2021 | |
| Piperacillin Sodium and Tazobactam Sodium for Injection(4:1) | 国药准字H20110134 | 化学药品 | 注射剂 | 3/19/2021 | |
| Piperacillin Sodium and Tazobactam Sodium for Injection(4:1) | 国药准字H20213901 | 化学药品 | 注射剂 | 11/24/2021 | |
| Piperacillin Sodium and Tazobactam Sodium for Injection(4:1) | 国药准字H20110066 | 化学药品 | 注射剂 | 3/22/2021 | |
| Piperacillin Sodium and Tazobactam Sodium for Injection(4:1) | 国药准字H20110063 | 化学药品 | 注射剂 | 3/13/2020 | |
| Piperacillin Sodium and Tazobactam Sodium for Injection(4:1) | 国药准字H20110133 | 化学药品 | 注射剂 | 3/19/2021 | |
| Piperacillin Sodium and Tazobactam Sodium for Injection(4:1) | 国药准字H20143181 | 化学药品 | 注射剂 | 3/13/2020 | |
| Piperacillin Sodium and Tazobactam Sodium for Injection(4:1) | 国药准字H20110065 | 化学药品 | 注射剂 | 3/22/2021 | |
| Piperacillin Sodium and Tazobactam Sodium for Injection(4:1) | 国药准字H20133235 | 化学药品 | 注射剂 | 3/13/2020 | |
| Piperacillin Sodium and Tazobactam Sodium for Injection(4:1) | 国药准字H20213899 | 化学药品 | 注射剂 | 11/24/2021 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.